amyloidosis: A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
136 |
4. Check minimum number of eventsNone |
136 |
5. Include endpointsNone |
136 |
6. Filter based on genotype QC (FinnGen only) |
136 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E85
- Name in latin
- Amyloidosis in uno organo
Similar endpoints
↥List of similar endpoints to
Organ-limited amyloidosis
based on the number of shared cases.
Similar with more cases:
- Amyloidosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1581 | 719 | 850 |
| Only index persons | 1221 | 545 | 676 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 83.24 | 84.01 | 82.64 |
| Only index persons | 83.19 | 84.14 | 82.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 136 | 46 | 90 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 76.01 | 69.60 | 79.28 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 106
- Matched controls
- 1059
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E85.4
ICD-10 Finland
Organ-limited amyloidosis
+∞
152.9
106
*
E85.9
ICD-10 Finland
Amyloidosis, unspecified
+∞
36.6
33
*
I43.1*E85.9
ICD-10 Finland
Cardiac amyloidosis
+∞
12.8
12
*
E85.89
ICD-10 Finland
Other amyloidosis
+∞
11.7
11
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.0
10.7
39
110
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
8.5
63
315
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.2
8.1
22
43
I50.0
ICD-10 Finland
Congestive heart failure
4.7
7.5
26
68
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.0
7.4
24
58
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
42.9
6.9
8
*
I43.1
ICD-10 Finland
Cardiomyopathy in metabolic diseases
+∞
6.3
6
*
N08.4*E85.9
ICD-10 Finland
Glomerular disorders in amyloidosis
+∞
6.3
6
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.5
6.3
31
111
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
23
20.14
41.49
5.5
2.5
54.6
33.9
mg/l
0.56
29
16
35
23
20.14
41.49
5.5
2.5
34.6
348.9
mg/l
0.48
29
16
22
38
6.71
12.72
3.7
1.4
—
—
—
0
0
22
38
6.71
12.72
3.7
1.4
7.1
7.5
g/l
0.67
17
30
10
10
10.71
8.75
2.0
1.5
—
—
—
0
0
22
61
4.11
7.38
7.7
2.7
165.3
94.0
ng/l
1.35
17
51
26
88
3.42
6.54
4.7
3.2
2.2
2.0
mmol/l
0.15
21
67
49
240
2.63
6.39
4.5
2.4
412.8
4235.4
umol/l
0.79
43
195
32
143
2.62
4.89
2.8
2.0
29.3
29.7
s
0.12
32
138
77
505
2.21
4.87
14.2
5.0
1.2
1.2
mmol/l
0.02
68
417
10
20
5.32
4.86
1.8
1.1
0.2
0.2
g/l
—
10
20
10
21
5.06
4.61
1.8
1.2
1.2
1.1
g/l
—
10
21
68
432
2.15
4.58
6.3
3.9
74.4
42.6
ng/l
0.86
57
325
30
134
2.59
4.57
4.8
2.0
19.7
22.6
%
0.34
25
112
44
241
2.22
4.25
2.1
1.8
1017.1
1176.6
nmol/l
0.59
33
183
58
362
2.05
3.96
6.6
3.2
4443.4
1664.2
ng/l
2.67
52
303
9
15
6.34
3.88
1.9
1.1
—
—
—
0
0
65
427
2.00
3.81
8.3
3.4
32.7
34.4
g/l
1.15
60
388
15
51
3.18
3.71
6.7
4.7
25.5
25.3
mmol/l
0.07
15
51
10
27
3.92
3.42
1.9
1.1
—
—
—
0
0
10
28
3.78
3.26
1.6
1.1
—
—
—
0
0
13
45
3.09
3.12
1.7
2.8
—
—
—
0
0
42
253
1.96
3.04
2.6
2.2
3.4
3.4
mg/l
0.06
37
217
73
531
1.81
2.90
10.8
9.2
5.2
4.3
e9/l
1.16
66
458
7
15
4.86
2.63
2.1
2.7
228.9
183.9
%
—
7
15
9
220
0.37
2.61
2.3
1.6
1.1
1.2
mmol/l
—
9
166
31
177
1.97
2.59
1.7
1.8
—
—
—
0
0
17
76
2.41
2.56
2.8
1.4
—
—
—
0
0
51
345
1.77
2.51
4.1
2.5
178.9
156.7
ug/l
0.29
45
307
54
372
1.75
2.49
4.7
3.3
—
—
—
0
0
10
36
2.92
2.25
1.6
1.5
—
—
—
0
0
5
10
5.14
2.09
1.2
1.0
—
—
—
0
0
56
411
1.62
1.95
2.2
2.0
86.2
95.1
pmol/l
0.78
36
206
48
339
1.64
1.94
4.6
2.7
2.4
2.4
mmol/l
0.30
43
290
35
230
1.70
1.85
2.2
2.4
—
—
—
0
0
42
295
1.61
1.71
3.2
3.6
33.4
10.9
mg/mmol
1.05
29
175
31
201
1.70
1.71
1.9
1.7
1.7
1.6
mg/l
0.15
20
158
6
22
2.80
1.45
1.0
1.4
—
—
—
0
0
5
16
3.20
1.45
1.4
1.9
—
—
—
0
0
7
29
2.49
1.41
1.6
1.2
—
—
—
0
0
9
41
2.28
1.40
1.1
1.7
—
—
—
0
0
31
213
1.59
1.37
2.4
2.8
2.5
2.5
mmol/l
0.66
26
186
56
439
1.47
1.35
4.7
4.2
—
—
—
0
0
0
41
0.00
1.33
0.0
1.0
—
—
—
0
0
20
123
1.73
1.33
1.8
1.8
—
—
—
0
0
64
520
1.44
1.26
3.5
2.8
51.7
52.1
u/l
0.02
59
475
6
26
2.37
1.20
1.5
1.3
—
—
—
0
0
6
26
2.37
1.20
1.5
1.3
—
—
—
0
0
103
919
1.50
1.20
33.0
15.9
26.4
26.7
mg/l
0.04
92
740
21
137
1.63
1.14
1.4
1.2
56.1
53.5
iu/ml
—
6
33
23
154
1.59
1.13
3.9
2.8
2.5
1.8
e6/l
0.12
14
87
9
45
2.07
1.07
1.8
1.8
—
—
—
0
0
38
288
1.44
1.06
4.8
3.0
0.9
0.4
e6/l
0.62
32
217
6
27
2.28
0.94
5.7
1.4
—
—
—
0
0
11
63
1.81
0.93
1.3
1.4
—
—
—
0
0
31
232
1.44
0.92
1.6
1.8
511.1
432.7
pmol/l
0.64
26
190
18
122
1.55
0.85
1.8
1.8
—
—
—
0
0
56
473
1.31
0.79
4.2
4.1
0.0
0.0
estimate
0.00
15
86
5
23
2.22
0.77
3.2
1.1
34550.0
12816.7
e6/l
—
5
12
105
970
1.36
0.76
37.9
18.0
139.1
139.7
mmol/l
1.39
99
933
105
970
1.36
0.76
15.0
10.5
22.6
23.9
u/l
0.66
98
918
105
975
1.34
0.69
38.6
18.0
4.1
4.0
mmol/l
0.84
99
937
34
272
1.33
0.69
2.4
3.1
0.6
0.8
ug/l
0.83
26
187
18
129
1.46
0.67
1.4
1.3
3.9
8.2
u/ml
—
7
42
22
167
1.38
0.62
3.9
2.7
0.4
1.3
e6/l
2.26
13
100
6
35
1.75
0.58
2.0
2.6
23.9
25.3
mmol/l
—
6
26
10
69
1.48
0.45
1.8
1.7
—
—
—
0
0
8
56
1.45
0.43
3.4
2.1
1.1
1.1
%
—
8
56
8
58
1.40
0.42
4.6
1.6
1.9
1.7
%
—
8
42
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
17
134
1.31
0.39
2.8
4.4
32.7
31.5
%
0.18
12
83
42
370
1.20
0.38
3.7
4.7
20.7
21.5
%
0.14
22
195
52
468
1.18
0.37
5.8
5.3
0.0
0.0
estimate
0.00
15
86
46
410
1.18
0.37
2.1
2.5
—
—
—
0
0
52
470
1.17
0.35
4.2
4.0
0.0
0.0
estimate
0.00
15
92
12
94
1.30
0.29
6.8
3.6
1.2
1.2
mmol/l
0.07
12
81
16
132
1.24
0.27
18.4
8.4
—
—
—
0
0
94
905
1.13
0.22
4.7
5.1
2.5
2.6
mmol/l
1.27
82
790
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
5
70
0.70
0.17
2.2
1.4
—
—
—
0
0
49
461
1.10
0.16
4.6
5.2
4.0
5.6
ug/l
0.26
41
397
85
873
0.93
0.12
28.0
14.7
67.1
73.2
ml/min/173m2
1.18
69
714
92
898
1.08
0.11
4.8
5.0
5.8
6.0
mmol/l
1.09
82
783
88
858
1.07
0.11
5.4
6.1
41.3
40.7
mmol/mol
0.22
78
774
67
649
1.06
0.10
3.8
3.6
14.9
15.0
pmol/l
0.11
62
560
36
379
0.93
0.09
4.5
4.4
—
—
—
0
0
86
840
1.06
0.09
4.3
4.1
1.3
1.2
mmol/l
0.37
76
731
84
820
1.06
0.09
4.7
4.3
2.2
2.1
mu/l
0.48
74
707
9
84
1.08
0.07
1.1
1.4
—
—
—
0
0
86
869
0.97
0.02
4.7
4.5
1.4
1.5
mmol/l
1.25
77
762
11
104
1.06
0.01
5.6
3.8
—
—
—
0
0
28
276
1.02
0.00
4.6
4.4
0.0
0.0
estimate
0.00
11
84
88
877
1.01
0.00
4.7
4.6
4.2
4.5
mmol/l
2.25
80
781
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_AMYL_ORGAN and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_AMYL_ORGAN.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_AMYL_ORGAN – Organ-limited amyloidosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data